Aimmune (AIMT) Appoints Jeffrey H. Knapp As Chief Operating Officer

BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced the appointment of Jeffrey H. Knapp as Chief Operating Officer. Mr. Knapp brings a nearly 30-year track record of achievement in both large pharmaceutical and small biotechnology companies, including deep commercial experience and first-product launches. Mr. Knapp will join Aimmune on or about February 1, 2016.

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.